Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

DNA2.0 Licenses piggyBac System

By Drug Discovery Trends Editor | May 24, 2012

DNA2.0, the leading bioengineering solutions provider, introduced the piggyBac Mammalian Expression System, an efficient, one plasmid method to create stable transfectants in mammalian cells. Licensed from Transposagen Biopharmaceuticals Inc., the piggyBac transposon system includes reversible genetic modification and rapid insertion site characterization. DNA2.0 scientists have taken Transposagen’s best-in-class genetic modification system and optimized it for the company’s all-in-one pHULK vectors. Applications range from stem cell research to protein production and cell line engineering.

“By pairing powerful third-party solutions such as Transposagen’s piggyBac system with our world-class gene design expertise and industry-leading gene synthesis, DNA2.0 can ensure that our customers have the competitive edge,” said Claes Gustafsson, cofounder and Chief Commercial Officer of DNA2.0.

DNA2.0’s piggyBac vectors are the first to come with CometGFP, a green fluorescent protein for easy confirmation of transfection, protein production, or cellular localization. pHULK piggyBac mammalian expression vectors are available as catalog items and for custom cloning for synthetic genes. Like all DNA2.0 products, pHULK vectors are manufactured at the company’s facility in Menlo Park, California. DNA2.0 customers maintain full rights to their intellectual property.

Date: May 24, 2012
Source: DNA2.0


Filed Under: Drug Discovery

 

Related Articles Read More >

Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority
Portrait photo of Pfizer EVP and Medtronic board member Lidia Fonseca
Medtronic appoints Pfizer EVP as independent board director

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50